108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
BK 多瘤病毒在肾脏疾病中的流行情况：与免疫抑制剂及淋巴细胞亚群的关系
Authors Wang Z, Zhao J, Kong L, Liu C, Lv Z, Wang Y, Dou Y, You X
Received 20 June 2025
Accepted for publication 18 September 2025
Published 29 September 2025 Volume 2025:18 Pages 5149—5160
DOI https://doi.org/10.2147/IDR.S548434
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yan Li
Ziran Wang,1,* Jiawei Zhao,2,* Lingjun Kong,1 Cun Liu,3 Zhou Lv,4 Yanhong Wang,2 Yaling Dou,1 Xin You5
1Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Geriatric I, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, People’s Republic of China; 3Department of Clinical Laboratory, The Affiliated Qingdao Third People’s Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of China; 4Department of Clinical Laboratory, Huangshi Aikang Hospital, Huangshi, Hubei, People’s Republic of China; 5Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yaling Dou, Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, People’s Republic of China, Email douyl@pumch.cn Xin You, Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China, Email youxin@pumch.cn
Background: BK polyomavirus (BKV), a latent pathogen in immunocompromised individuals, poses significant risks in renal-associated diseases (RD).
Methods: This study recruited 88 healthy control (HC) individuals and 271 patients with RD, including 96 connective tissue diseases with renal involvement (CTD-RI), 90 chronic kidney disease (CKD), 66 urological tumors (UT), 19 kidney transplantation (KT), at Peking Union Medical College Hospital from January 2020 to September 2021. The BKV-DNA qPCR detection kit was evaluated in terms of lowest detection limit, linear range, accuracy, precision, analytical specificity. Urine, serum, and plasma specimens from 17 UT patients were detected simultaneously to evaluate the detection sensitivity of various sample types. The positive rates and loads of BKV-DNA were compared among the various groups. The difference in immunosuppressants use between BKV-DNA positive and negative groups was compared in patients with CTD-RI. Furthermore, the correlations between BKV-DNA loads and the counts of lymphocyte subsets were explored in the CTD-RI group.
Results: The BKV-DNA qPCR detection kit has satisfactory sensitivity, linear range, reproducibility, accuracy, and specificity to detect the presence and loads of BKV-DNA. Urine specimens are more sensitive for BKV-DNA detection than serum and plasma. The CTD-RI and UT groups had higher BKV-DNA positive rates (49.0% and 31.8%, respectively) and loads (median: 5.69 log10 copies/mL and 6.03 log10 copies/mL, respectively) compared to the HC group (positive rate 12.5%, load median 3.96 log10 copies/mL). Multivariate logistic regression analysis indicated that the use of mycophenolate mofetil (MMF) was associated with a reduced risk of BKV (odds ratio and 95% confidence interval: 0.27 (0.09– 0.78), P=0.015). The trends toward negative correlations between the BKV-DNA loads and the counts of CD19+ B cells, CD4+CD28+ T cells, CD45RA+CD4+ T cells, and naive CD4+ T cells were observed.
Conclusion: These findings support monitoring BKV-DNA in high-risk RD patients to guide immunosuppressant use and mitigate renal injury. Future long-term follow-up and multicenter large-scale cohort studies are necessary to further clarify the role of BKV in RD.
Keywords: BK polyomavirus, renal associated diseases, immunosuppressant, immune cells
1Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Geriatric I, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, People’s Republic of China; 3Department of Clinical Laboratory, The Affiliated Qingdao Third People’s Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of China; 4Department of Clinical Laboratory, Huangshi Aikang Hospital, Huangshi, Hubei, People’s Republic of China; 5Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yaling Dou, Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, People’s Republic of China, Email douyl@pumch.cn Xin You, Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China, Email youxin@pumch.cn
Background: BK polyomavirus (BKV), a latent pathogen in immunocompromised individuals, poses significant risks in renal-associated diseases (RD).
Methods: This study recruited 88 healthy control (HC) individuals and 271 patients with RD, including 96 connective tissue diseases with renal involvement (CTD-RI), 90 chronic kidney disease (CKD), 66 urological tumors (UT), 19 kidney transplantation (KT), at Peking Union Medical College Hospital from January 2020 to September 2021. The BKV-DNA qPCR detection kit was evaluated in terms of lowest detection limit, linear range, accuracy, precision, analytical specificity. Urine, serum, and plasma specimens from 17 UT patients were detected simultaneously to evaluate the detection sensitivity of various sample types. The positive rates and loads of BKV-DNA were compared among the various groups. The difference in immunosuppressants use between BKV-DNA positive and negative groups was compared in patients with CTD-RI. Furthermore, the correlations between BKV-DNA loads and the counts of lymphocyte subsets were explored in the CTD-RI group.
Results: The BKV-DNA qPCR detection kit has satisfactory sensitivity, linear range, reproducibility, accuracy, and specificity to detect the presence and loads of BKV-DNA. Urine specimens are more sensitive for BKV-DNA detection than serum and plasma. The CTD-RI and UT groups had higher BKV-DNA positive rates (49.0% and 31.8%, respectively) and loads (median: 5.69 log10 copies/mL and 6.03 log10 copies/mL, respectively) compared to the HC group (positive rate 12.5%, load median 3.96 log10 copies/mL). Multivariate logistic regression analysis indicated that the use of mycophenolate mofetil (MMF) was associated with a reduced risk of BKV (odds ratio and 95% confidence interval: 0.27 (0.09– 0.78), P=0.015). The trends toward negative correlations between the BKV-DNA loads and the counts of CD19+ B cells, CD4+CD28+ T cells, CD45RA+CD4+ T cells, and naive CD4+ T cells were observed.
Conclusion: These findings support monitoring BKV-DNA in high-risk RD patients to guide immunosuppressant use and mitigate renal injury. Future long-term follow-up and multicenter large-scale cohort studies are necessary to further clarify the role of BKV in RD.
Keywords: BK polyomavirus, renal associated diseases, immunosuppressant, immune cells